Non-coding RNA Research,
Journal Year:
2020,
Volume and Issue:
5(4), P. 222 - 231
Published: Nov. 21, 2020
Coronavirus
disease
2019
(COVID-19)
caused
by
a
novel
betacoronavirus
named
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
has
attracted
top
health
concerns
worldwide
within
few
months
after
its
appearance.
Since
viruses
are
highly
dependent
on
the
host
small
RNAs
(microRNAs)
for
their
replication
and
propagation,
in
this
study,
miRNAs
targeting
SARS-CoV-2
genome
differentially
expressed
genes
(DEGs)
lungs
of
patients
infected
with
SARS-CoV-2,
were
predicted.
Theranostics,
Journal Year:
2020,
Volume and Issue:
11(4), P. 1690 - 1702
Published: Dec. 16, 2020
The
global
outbreak
of
a
novel
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
highlighted
requirement
for
two
pronged
clinical
interventions
such
as
development
effective
vaccines
and
therapeutic
options
medium-to-severe
stages
"coronavirus
disease
2019"
(COVID-19).
Effective
vaccines,
if
successfully
developed,
have
been
emphasized
to
become
the
most
strategy
in
fight
against
COVID-19
pandemic.
Basic
research
advances
biotechnology
genetic
engineering
already
provided
excellent
progress
groundbreaking
new
discoveries
field
biology
its
epidemiology.
In
particular,
vaccine
characterization
capsid
structure
identification
antigens
that
can
targets
vaccines.
experimental
requires
plethora
molecular
techniques
well
strict
compliance
with
safety
procedures.
data
integrity,
cross-validation
results,
appropriated
studies
from
perspective
efficacy
potently
side
effects
recently
hotly
discussed
topic.
this
review,
we
present
an
update
on
latest
ongoing
race
develop
52
different
SARS-CoV-2.
Our
analysis
is
focused
registered
trials
(current
November
04,
2020)
fulfill
international
criteria
development.
requirements
benefits
risks
diverse
types
SARS-CoV-2
are
including
those
containing
whole-virus
live-attenuated
subunit
mRNA
DNA
live
vector
also
plant-based
formulation
coronavirus-like
particle
(VLP).
challenges
associated
distribution,
long-term
effectiveness
discussed.
PLoS Biology,
Journal Year:
2021,
Volume and Issue:
19(6), P. e3001265 - e3001265
Published: June 18, 2021
The
search
for
potential
antibody-based
diagnostics,
vaccines,
and
therapeutics
pandemic
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
has
focused
almost
exclusively
on
the
spike
(S)
nucleocapsid
(N)
proteins.
Coronavirus
membrane
(M),
ORF3a,
ORF8
proteins
are
humoral
immunogens
in
other
coronaviruses
(CoVs)
but
remain
largely
uninvestigated
SARS-CoV-2.
Here,
we
use
ultradense
peptide
microarray
mapping
to
show
that
SARS-CoV-2
infection
induces
robust
antibody
responses
epitopes
throughout
proteome,
particularly
M,
which
1
epitope
achieved
excellent
diagnostic
accuracy.
We
map
79
B
cell
proteome
demonstrate
antibodies
develop
response
bind
homologous
sequences
6
known
human
CoVs.
also
confirm
reactivity
against
4
of
our
top-ranking
by
enzyme-linked
immunosorbent
assay
(ELISA).
Illness
severity
correlated
with
increased
9
S,
N,
ORF3a
population.
Our
results
previously
unknown,
highly
reactive
full
CoV
Scientific Reports,
Journal Year:
2021,
Volume and Issue:
11(1)
Published: Jan. 8, 2021
Abstract
SARS-CoV-2
induces
a
muted
innate
immune
response
compared
to
other
respiratory
viruses.
Mitochondrial
dynamics
might
partially
mediate
this
effect
of
on
immunity.
Polypeptides
encoded
by
open
reading
frames
SARS-CoV
and
have
been
shown
localize
mitochondria
disrupt
Antiviral
Signaling
(MAVS)
protein
signaling.
Therefore,
we
hypothesized
that
would
distinctly
regulate
the
mitochondrial
transcriptome.
We
analyzed
multiple
publicly
available
RNASeq
data
derived
from
primary
cells,
cell
lines,
clinical
samples
(i.e.,
BALF
lung).
report
did
not
dramatically
(1)
mtDNA-encoded
gene
expression
or
(2)
MAVS
expression,
(3)
downregulated
nuclear-encoded
(NEM)
genes
related
cellular
respiration
Complex
I.
The Journal of Physical Chemistry Letters,
Journal Year:
2020,
Volume and Issue:
11(22), P. 9659 - 9668
Published: Nov. 2, 2020
SARS-CoV-2
is
the
cause
of
ongoing
Coronavirus
disease
19
(COVID-19)
pandemic
around
world
causing
pneumonia
and
lower
respiratory
tract
infections.
In
understanding
pathogenicity
mechanism
action,
it
essential
to
depict
full
repertoire
expressed
viral
proteins.
The
recent
biological
studies
have
highlighted
leader
protein
Nsp1
importance
in
shutting
down
host
production.
Besides,
still
enigmatic
how
regulates
for
translation.
Here
we
report
novel
structure
from
complex
with
SL1
region
5'UTR
SARS-CoV-2,
its
factual
interaction
corroborated
enzyme
kinetics
experimental
binding
affinity
studies.
also
address
recognizes
self
RNA
toward
translational
regulation
by
further
recruitment
40S
ribosome.
With
aid
molecular
dynamics
simulations,
demonstrated
real-time
stability
functional
Nsp1/SL1
complex.
potential
inhibitors
their
mode
action
block
protein/RNA
formation.
This
enhance
our
first
synthesized
human
cell
regulate
translation
host.
Understanding
interplay
ribosome
will
open
arena
exploring
development
live
attenuated
vaccines
effective
therapeutic
targets
this
disease.
Non-coding RNA Research,
Journal Year:
2020,
Volume and Issue:
5(4), P. 222 - 231
Published: Nov. 21, 2020
Coronavirus
disease
2019
(COVID-19)
caused
by
a
novel
betacoronavirus
named
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
has
attracted
top
health
concerns
worldwide
within
few
months
after
its
appearance.
Since
viruses
are
highly
dependent
on
the
host
small
RNAs
(microRNAs)
for
their
replication
and
propagation,
in
this
study,
miRNAs
targeting
SARS-CoV-2
genome
differentially
expressed
genes
(DEGs)
lungs
of
patients
infected
with
SARS-CoV-2,
were
predicted.
